Therefore, to further evaluate potential fungi- and CLR-mediated immune regulation in immune cells in bladder cancer and explore its impact on ICB therapy efficacy, we conducted a TIMER analysis to specifically explore the association between CLRs and some immune cells, as shown in Figures 5A–E. The gene discussed is LARS1; the disease is urinary bladder carcinoma.